País: Canadá
Língua: inglês
Origem: Health Canada
AZITHROMYCIN
GENMED A DIVISION OF PFIZER CANADA ULC
J01FA10
AZITHROMYCIN
100MG
POWDER FOR SUSPENSION
AZITHROMYCIN 100MG
ORAL
(300MG/15ML)
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0126072002; AHFS:
CANCELLED POST MARKET
2019-11-08
PRODUCT MONOGRAPH PR GD ® -AZITHROMYCIN azithromycin dihydrate *Azithromycin tablets 250 mg *Azithromycin for oral suspension 100 mg/5 mL, 200 mg/5 mL (* as azithromycin dihydrate) Antibacterial Agent GenMed, a division of Pfizer Canada Inc. 17300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No. 220807 GD ® is a trademark of Pfizer Canada Inc. GenMed, a division of Pfizer Canada Inc., Licensee Product Licensed from Pliva, Zagreb, Croatia Date of Revision: October 15, 2018 _GD-AZITHROMYCIN (azithromycin dihydrate) Product Monograph Page 2 of 74_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................6 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ............................................................25 STORAGE AND STABILITY ..........................................................................................28 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................28 PART II: SCIENTIFIC INFORMATION ...............................................................................30 PHARMACEUTICAL INFORMATION ........ Leia o documento completo